肿瘤免疫抑制微环境对肿瘤免疫治疗作用的研究进展

doi:10.11904/j.issn.1002-3070.2016.02.016

摘要/Abstract

摘要： 肿瘤免疫抑制微环境是肿瘤微环境中起抑制免疫功能的部分。其组成包括抑制性细胞和抑制性细胞因子。近年来,因其在肿瘤免疫中的重要作用,CAR-T和PD-1/PD-L1信号通路已成为免疫治疗的研究热点,它们可通过不同的机制产生免疫抑制作用,从而促进肿瘤进展。因此,针对以上机制采取更有效的抗肿瘤疗法有可能减缓肿瘤进展。本文现就免疫抑制微环境对CAR-T疗法和PD-1/PD-L1信号通路在抗肿瘤过程中的作用进行综述。

关键词: 免疫抑制微环境, 免疫治疗, 嵌合抗原受体T细胞, 程序死亡分子1, 程序死亡分子1配体

Abstract: Immunosuppressive tumor microenvironment is a part of the tumor microenvironment that plays an immunosuppressive function.It consists of suppressor cells and inhibitory cytokines.In recent years,because of its important role in tumor immunity,CAR-T and PD-1/PD-L1 signal pathway has become a hot topic of immunotherapy,which can suppress immune through different mechanisms to promote tumor progression.Therefore,taking more effective anti-tumor therapies against the above mechanisms is possible to rescue the progress of tumor.In this article,the influence of immunosuppression microenvironment in CAR-T cell therapy and PD-1/PD-L1 signaling pathway in the anti-tumor process is reviewed.

Key words: Immunosuppressive microenvironment, Immunotherapy, Chimeric antigen receptor T cell, Programmed death 1, Programmed death 1 ligand

中图分类号:

R730.3

张锐, 王智煜, 文孝婷综述, 赵晖审校. 肿瘤免疫抑制微环境对肿瘤免疫治疗作用的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 167-171.

ZHANG Rui, WANG Zhiyu, WEN Xiaoting, ZHAO Hui. Study progresses of tumor immunosuppressive microenvironment in tumor immunotherapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 167-171.

参考文献

1 Shore ND.Advances in the understanding of cancer immunotherapy[J].BJU Int,2015,116(3):321-329.
2 Frey AB.Suppression of T cell responses in the tumor microenvironment[J].Vaccine,2015,16;33(51):7393-7400.
3 Ostrand-Rosenberg S,Sinha P,Beury DW,et al.Cross-talk between myeloid-derived suppressor cells(MDSC),macrophages,and dendritic cells enhances tumor-induced immune suppression[J].Semin Cancer Biol,2012,22(4):275-281.
4 Qiao J,Dey M,Chang AL,et al.Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy[J].Oncoimmunology,2015,24(8):e1022302.
5 Soleymaninejadian E,Pramanik K,Samadian E.Immunomodulatory properties of mesenchymal stem cells:cytokines and factors[J].Am J Reprod Immunol,2012,67(1):1-8.
6 Lindau D,Gielen P,Kroesen M,et al.The immunosuppressive tumour network:myeloid-derived suppressor cells,regulatory T cells and natural killer T cells[J].Immunology,2013,138(2):105-115.
7 Madureira P,de Mello RA,de Vasconcelos A,et al.Immunotherapy for lung cancer:for whom the bell tolls?[J].Tumour Biol,2015,36(3):1411-1422.
8 Jiang T,Zhou C.The past,present and future of immunotherapy against tumor[J].Transl Lung Cancer Res,2015,4(3):253-264.
9 Anurathapan U,Leen AM,Brenner MK,et al.Engineered T cells for cancer treatment[J].Cytotherapy,2014,16(6):713-733.
10 Turnis ME,Andrews LP,Vignali DA.Inhibitory receptors as targets for cancer immunotherapy[J].Eur J Immunol,2015,45(7):1892-1905.
11 Kohn DB,Dotti G,Brentjens R,et al.CARs on track in the clinic[J].Mol Ther,2011,19(3):432-438.
12 Park TS,Rosenberg SA,Morgan RA.Treating cancer with genetically engineered T cells[J].Trends Biotechnol,2011,29(11):550-557.
13 Bezbradica JS,Medzhitov R.Role of ITAM signaling module in signal integration[J].Curr Opin Immunol,2012,24(1):58-66.
14 Hombach AA,Abken H.Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling[J].Int J Cancer,2011,129(12):2935-2944.
15 Song DG,Ye Q,Carpenito C,et al.In vivo persistence,tumor localization,and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137(4-1BB)[J].Cancer Res,2011,71(13):4617-4627.
16 Zhong XS,Matsushita M,Plotkin J,et al.Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication[J].Mol Ther,2010,18(2):413-420.
17 Weber J.Immune checkpoint proteins:a new therapeutic paradigm for cancer-preclinical background:CTLA-4 and PD-1 blockade[J].Semin Oncol,2010,37(5):430-439.
18 Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
19 Okudaira K,Hokari R,Tsuzuki Y,et al.Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model[J].Int J Oncol,2009,35(4):741-749.
20 Tang X,Li Q,Zhu Y,et al.The advantages of PD1 activating chimeric receptor(PD1-ACR)engineered lymphocytes for PDL1(+)cancer therapy[J].Am J Transl Res,2015,7(3):460-473.
21 Dulos J,Carven GJ,van Boxtel SJ,et al.PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer[J].J Immunother,2012,35(2):169-178.
22 Wallecha A,Singh R,Malinina I.Listeria monocytogenes(Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment[J].J Immunother,2013,36(9):468-476.
23 Gabrilovich DI,Ostrand-Rosenberg S,Bronte V.Coordinated regulation of myeloid cells by tumours[J].Nat Rev Immunol,2012,12(4):253-268.
24 Luo X,Yang H,Kim IS,et al.Systemic transforming growth factor-beta1 gene therapy induces Foxp3+ regulatory cells,restores self-tolerance,and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice[J].Transplantation,2005,79(9):1091-1096.
25 Perruche S,Zhang P,Liu Y,et al.CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells[J].Nat Med,2008,14(5):528-535.
26 Tang Q,Bluestone JA.The Foxp3+ regulatory T cell:a jack of all trades,master of regulation[J].Nat Immunol,2008,9(3):239-244.
27 程爱荣,孙保亮.调节性T细胞及其免疫抑制机制[J].中国临床神经科学,2014,22(4):438-444.
28 Yang W,Song Y,Lu YL,et al.Increased expression of programmed death(PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia[J].Immunology,2013,139(4):513-522.
29 Francisco LM1,Sage PT,Sharpe AH.The PD-1 pathway in tolerance and autoimmunity[J].Immunol Rev,2010,236:219-242.
30 Flies DB,Chen L.The new B7s:playing a pivotal role in tumor immunity[J].J Immunother,2007,30(3):251-260.
31 邹征云,蔡慧.嵌合抗原受体基因修饰 T 淋巴细胞在肿瘤免疫治疗中的研究[J].现代肿瘤医学,2014,22(11):2730-2734.
32 罗晓玲,陈杰,王罗.嵌合抗原受体T细胞介绍及抗肿瘤临床应用[J].中国细胞生物学学报,2014,36(2):228-235.
33 Topalian SL,Hodi FS,Brahmer JR,et al.Safety,activity,and immune correlates of anti-PD-1 antibody in cancer[J].N Engl J Med,2012,366(26):2443-2454.
34 John LB,Kershaw MH,Darcy PK.Blockade of PD-1 immunosuppression boosts CAR T-cell therapy[J].Oncoimmunology,2013,2(10):e26286.

[1]	孙祖刚, 王哲, 陈怀安, 刘硕, 苗文隆. 诱发膀胱癌的常见慢性炎症因素及其免疫治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 357-361.
[2]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[3]	苗素平, 郭二亮, 裴荣, 姜寰宇, 苗素生. miRNA调节免疫检查点在肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 57-62.
[4]	曾玉兰,刘洋洋,梁金燕,谷飞飞,刘莉. 免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 353-358.
[5]	刘珈杞，刘耀华，陈鑫，综述，赵世光，审校. CD4⁺CD25⁺Foxp3⁺Treg细胞调控肿瘤免疫抑制微环境的研究进展[J]. 实用肿瘤学杂志, 2016, 30(6): 555-559.
[6]	黄娟娟, 王雯欣综述, 曹峰林审校. 血液系统恶性肿瘤细胞免疫治疗的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 61-65.
[7]	全丽娜,刘爱春,郭秀臣,李莲乔,贾垂明. B非霍奇金淋巴瘤患者Th17、Treg水平及Th17/Treg失衡的研究[J]. 实用肿瘤学杂志, 2013, 27(5): 400-405.
[8]	赵丽娜, 全丽娜, 郭秀臣, 刘爱春. 重组鼠CD40配体的Ankara痘病毒疫苗对鼠淋巴瘤的免疫治疗作用的研究[J]. 实用肿瘤学杂志, 2013, 27(4): 308-312.
[9]	张晶岩, 于友涛, 赵宪, 李海斌, 宋浩. 介入联合手术切除及免疫疗法治疗中晚期巨大肾癌[J]. 实用肿瘤学杂志, 2012, 26(6): 519-523.
[10]	武丽华, 王东亮, 张艳桥. 髓源性抑制细胞——肿瘤免疫治疗的新靶点[J]. 实用肿瘤学杂志, 2012, 26(4): 369-372.
[11]	刘艳艳, 王东亮, 张艳桥. 调节性T细胞与恶性肿瘤的过继免疫治疗[J]. 实用肿瘤学杂志, 2012, 26(2): 173-177.
[12]	王振坤, 曹峰林. CIK细胞抗白血病的研究进展[J]. 实用肿瘤学杂志, 2011, 25(1): 10-13.
[13]	周艳华, 张艳桥. 树突状细胞在肺癌免疫治疗中的研究进展[J]. 实用肿瘤学杂志, 2011, 25(1): 18-21.
[14]	徐京京, 张艳桥. DC-CIK细胞在乳腺癌治疗中的研究现状[J]. 实用肿瘤学杂志, 2011, 25(1): 26-28.
[15]	纪亚红综述, 崔亚利审校. 肿瘤放射免疫靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2008, 22(6): 590-594.